James E. Flynn - 11 Nov 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
10%+ Owner
Signature
/s/ Jonathan Isler, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
11 Nov 2024
Net transactions value
-$10,143,706
Form type
4
Filing time
13 Nov 2024, 20:16:26 UTC
Previous filing
24 Oct 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Class A Common Stock Sale $708,400 -40,596 -0.73% $17.45 5,498,368 11 Nov 2024 Through Deerfield Private Design Fund III, L.P. F1, F2, F3
transaction SPRY Class A Common Stock Sale $708,400 -40,596 -0.73% $17.45 5,498,367 11 Nov 2024 Through Deerfield Private Design Fund IV, L.P. F1, F2, F3
transaction SPRY Class A Common Stock Sale $4,058,921 -223,632 -4.1% $18.15 5,274,736 11 Nov 2024 Through Deerfield Private Design Fund III, L.P. F2, F3, F4
transaction SPRY Class A Common Stock Sale $4,058,921 -223,632 -4.1% $18.15 5,274,735 11 Nov 2024 Through Deerfield Private Design Fund IV, L.P. F2, F3, F4
transaction SPRY Class A Common Stock Sale $134,757 -7,853 -0.15% $17.16 5,266,883 12 Nov 2024 Through Deerfield Private Design Fund III, L.P. F2, F3, F5
transaction SPRY Class A Common Stock Sale $134,775 -7,854 -0.15% $17.16 5,266,881 12 Nov 2024 Through Deerfield Private Design Fund IV, L.P. F2, F3, F5
transaction SPRY Class A Common Stock Sale $169,775 -9,554 -0.18% $17.77 5,257,329 12 Nov 2024 Through Deerfield Private Design Fund III, L.P. F2, F3, F6
transaction SPRY Class A Common Stock Sale $169,757 -9,553 -0.18% $17.77 5,257,328 12 Nov 2024 Through Deerfield Private Design Fund IV, L.P. F2, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.90 to $17.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 4, 5 and 6 of this Form 4.
F2 This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P.
F3 In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
F4 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.51, inclusive.
F5 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.68 to $17.65, inclusive.
F6 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.69 to $17.82, inclusive.

Remarks:

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P. and James E. Flynn.